• AstraZeneca disclosed Phase III HICKORY results for efzimfotase alfa in hypophosphatasia; findings were presented today at ASBMR 2026.
• The study missed its main goal versus placebo, though treated patients showed signs of better walking ability.
• Several secondary measures suggested benefits in fatigue and pain, with improvements continuing in the extension period.
• The drug has U.S. FDA Priority Review, positioning it as a potential new option in a rare-disease market now served by Strensiq.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief via Cision (Ref. ID: 202610111701BITN____UKPR__SV_20261011-BIT-1681-0) on October 11, 2026, and is solely responsible for the information contained therein.